Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

Gushchin, V.A.; Dolzhikova, I.V.; Shchetinin, A.M.; Odintsova, A.S.; Siniavin, A.E.; Nikiforova, M.A.; Pochtovyi, A.A.; Shidlovskaya, E.V.; Kuznetsova, N.A.; Burgasova, O.A.; Kolobukhina, L.V.; Iliukhina, A.A.; Kovyrshina, A.V.; Botikov, A.G.; Kuzina, A.V.; Grousova, D.M.; Tukhvatulin, A.I.; Shcheblyakov, D.V.; Zubkova, O.V.; Karpova, O.V.; Voronina, O.L.; Ryzhova, N.N.; Aksenova, E.I.; Kunda, M.S.; Lioznov, D.A.; Danilenko, D.M.; Komissarov, A.B.; Tkachuck, A.P.; Logunov, D.Y.; Gintsburg, A.L.

Авторы: Gushchin Vladimir A., Dolzhikova Inna V., Shchetinin Alexey M., Odintsova Alina S., Siniavin Andrei E., Nikiforova Maria A., Pochtovyi Andrei A., Shidlovskaya Elena V., Kuznetsova Nadezhda A., Burgasova Olga A., Kolobukhina Liudmila V., Iliukhina Anna A., Kovyrshina Anna V., Botikov Andrey G., Kuzina Aleksandra V., Grousova Daria M., Tukhvatulin Amir I., Shcheblyakov Dmitry V., Zubkova Olga V., Karpova Oksana V., Voronina Olga L., Ryzhova Natalia N., Aksenova Ekaterina I., Kunda Marina S., Lioznov Dmitry A., Danilenko Daria M., Komissarov Andrey B., Tkachuck Artem P., Logunov Denis Y., Gintsburg Alexander L.
Журнал: VACCINES
Том: 9
Номер: 7
Год издания: 2021
Первая страница: 779
Последняя страница: 779
DOI: 10.3390/vaccines9070779
Аннотация: Since the beginning of the 2021 year, all the main six vaccines against COVID-19 have been used in mass vaccination companies around the world. Virus neutralization and epidemiological efficacy drop obtained for several vaccines against the B.1.1.7, B.1.351 P.1, and B.1.617 genotypes are of concern. There is a growing number of reports on mutations in receptor-binding domain (RBD) increasing the transmissibility of the virus and escaping the neutralizing effect of antibodies. The Sputnik V vaccine is currently approved for use in more than 66 countries but its activity against variants of concern (VOC) is not extensively studied yet. Virus-neutralizing activity (VNA) of sera obtained from people vaccinated with Sputnik V in relation to internationally relevant genetic lineages B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3 and Moscow endemic variants B.1.1.141 (T385I) and B.1.1.317 (S477N, A522S) with mutations in the RBD domain has been assessed. The data obtained indicate no significant differences in VNA against B.1.1.7, B.1.617.3 and local genetic lineages B.1.1.141 (T385I), B.1.1.317 (S477N, A522S) with RBD mutations. For the B.1.351, P.1, and B.1.617.2 statistically significant 3.1-, 2.8-, and 2.5-fold, respectively, VNA reduction was observed. Notably, this decrease is lower than that reported in publications for other vaccines. However, a direct comparative study is necessary for a conclusion. Thus, sera from “Sputnik V”-vaccinated retain neutralizing activity against VOC B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3 as well as local genetic lineages B.1.1.141 and B.1.1.317 circulating in Moscow
Добавил в систему: Гущин Владимир Алексеевич

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ЦЭМИ РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИСТИНА ЦЭМИ РАН

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variantsстатья